摘要
目的观察多西他赛联合表阿霉素治疗晚期乳腺癌的临床疗效及毒副作用,并对其安全性进行评估。方法用多西他赛联合表阿霉素治疗晚期乳腺癌患者41例,其中初治患者18例,复治患者23例。结果41例患者中,3例达到完全缓解,21例部分缓解,9例病情稳定,8例出现进展,其中有效率达58.5%,临床获益率达80.5%。结论多西他赛联合表阿霉素对晚期乳腺癌具有较好的疗效和耐受性,可作为晚期乳腺癌的解救方案。
OBJECTIVE To evaluate the afficaey, toxicity and safety of doeetaxel and epirubiein in the treatment of advanced breast caner. METHODS A total of 41 patients with advanced breast cancer proved pathologically were treated on with docetaxel and epirubiein regimen, among whom 18 patients were subjected to initially treatment, other 23 to reteatment. RESULTS Of the 41 patients, 3 achieved CR, 21 PR, 9 SD and 8 PD, with a response rate of 58.5% and 80.5%. CONCLUSIONS The regimen of doeetaxel and epirubicin is effective and well-tolerated in the treatment of advanced breast cancer. It may be a relevant regimen for patients.
出处
《中国初级卫生保健》
2009年第7期92-93,共2页
Chinese Primary Health Care
